MCID: GST050
MIFTS: 56

Gastrointestinal System Disease

Categories: Gastrointestinal diseases

Aliases & Classifications for Gastrointestinal System Disease

MalaCards integrated aliases for Gastrointestinal System Disease:

Name: Gastrointestinal System Disease 12 15
Gastrointestinal Diseases 54 71
Gastrointestinal Disease 12 17
Gastrointestinal Disorders 15
Digestive System Disorders 71
Alimentary System Disease 12
Digestive System Disorder 12
Gastrointestinal Disorder 12
Digestive System Diseases 43
Digestive System Disease 17
Gastroenteropathy 12
Git Disease 12

Classifications:



External Ids:

Disease Ontology 12 DOID:77
ICD9CM 34 520-579.99
MeSH 43 D004066
SNOMED-CT 67 53619000
ICD10 32 11 K92.8 K92.9
UMLS 71 C0012242 C0017178

Summaries for Gastrointestinal System Disease

Disease Ontology : 12 A disease of anatomical entity that is located in the gastrointestinal tract.

MalaCards based summary : Gastrointestinal System Disease, also known as gastrointestinal diseases, is related to intestinal disease and mouth disease, and has symptoms including vomiting, nausea and vomiting and abdominal pain. An important gene associated with Gastrointestinal System Disease is MIR199A1 (MicroRNA 199a-1), and among its related pathways/superpathways are MicroRNAs in cancer and SRF and miRs in Smooth Muscle Differentiation and Proliferation. The drugs Indomethacin and Acetaminophen have been mentioned in the context of this disorder. Affiliated tissues include gastrointestinal tract, testes and liver.

Wikipedia : 74 Gastrointestinal diseases (abbrev. GI diseases or GI illnesses) refer to diseases involving the... more...

Related Diseases for Gastrointestinal System Disease

Diseases related to Gastrointestinal System Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1071)
# Related Disease Score Top Affiliating Genes
1 intestinal disease 33.1 SERPINA3 MIR31 MIR21 MIR199A1 MIR196A1 MIR17
2 mouth disease 33.1 SERPINA3 MIR31 MIR21 MIR199A1 MIR196A1 MIR17
3 esophageal disease 33.1 MIR31 MIR21 MIR199A1 MIR196A1 MIR17 MIR145
4 gallbladder disease 33.1 SERPINA3 MLN MIR199A1 MIR196A1 MIR17 MIR145
5 stomach disease 33.0 S100A8 MLN MIR196A1 ICOSLG H2AC18 GAST
6 gastrointestinal ulceration, recurrent, with dysfunctional platelets 32.8 S100A8 GAST
7 pancreas disease 31.9 SERPINA3 MIR31 MIR21 MIR199A1 MIR196A1 MIR17
8 biliary tract disease 31.7 SERPINA3 MIR199A1 MIR196A1 MIR17 MIR145 MIR142
9 connective tissue disease 31.7 SERPINA3 MIR31 MIR21 MIR199A1 MIR196A1 MIR17
10 tongue disease 31.6 MIR31 MIR21 MIR199A1 MIR196A1 MIR17 MIR145
11 celiac disease 1 31.6 ICOSLG H2AC18 GAST CCR6 CCK
12 peptic esophagitis 31.6 S100A8 MLN GAST
13 pancreatic cancer 31.5 SERPINA3 MIR31 MIR21 MIR199A1 MIR196A1 MIR17
14 colorectal cancer 31.5 SERPINA3 MIR31 MIR21 MIR199A1 MIR196A1 MIR17
15 colonic disease 31.5 SERPINA3 MIR31 MIR21 MIR199A1 MIR196A1 MIR17
16 teeth hard tissue disease 31.4 SERPINA3 H2AC18 CCR6
17 esophageal cancer 31.4 MIR31 MIR21 MIR199A1 MIR196A1 MIR145 MIR143
18 body mass index quantitative trait locus 11 31.4 SERPINA3 MLN MIR21 MIR199A1 MIR196A1 MIR17
19 gastric cancer 31.3 SERPINA3 S100A8 MIR31 MIR21 MIR199A1 MIR196A1
20 salivary gland disease 31.3 SERPINA3 ICOSLG H2AC18 CCR6
21 myeloma, multiple 31.3 SERPINA3 MIR21 MIR199A1 MIR196A1 MIR17 MIR145
22 gastrointestinal system cancer 31.2 SERPINA3 MIR518A1 MIR31 MIR21 MIR199A1 MIR196A1
23 gastroparesis 31.2 MLN GAST CCK
24 systemic scleroderma 31.2 MLN MIR21 MIR142 ICOSLG H2AC18 GAST
25 non-alcoholic fatty liver disease 31.2 MIR31 MIR21 MIR199A1 MIR17 MIR126 MIR122
26 peripheral nervous system disease 31.2 SERPINA3 MIR21 MIR142 MIR126 ICOSLG H2AC18
27 hepatocellular carcinoma 31.2 SERPINA3 MIR31 MIR21 MIR199A1 MIR196A1 MIR17
28 skin disease 31.2 SERPINA3 MIR31 MIR21 MIR199A1 MIR196A1 MIR17
29 bone resorption disease 31.1 SERPINA3 MIR199A1 MIR196A1 MIR142 MIR122 H2AC18
30 duodenal ulcer 31.1 S100A8 MLN GAST CCK
31 microinvasive gastric cancer 31.1 S100A8 MIR196A1 GAST
32 psoriasis 31.0 S100A8 MIR31 MIR21 MIR17 MIR142 MIR122
33 collagen disease 31.0 SERPINA3 H2AC18 CCR6
34 exanthem 31.0 ICOSLG H2AC18 CCR6
35 bone disease 31.0 SERPINA3 ICOSLG H2AC18 CCR6
36 lymphoma, mucosa-associated lymphoid type 31.0 S100A8 MIR142 ICOSLG CCR6
37 cholangitis, primary sclerosing 31.0 MIR199A1 ICOSLG CCR6
38 rectum cancer 31.0 MIR518A1 MIR31 MIR21 MIR17 MIR145 MIR143
39 colorectal adenoma 30.9 MIR21 MIR17 APC
40 bacterial infectious disease 30.9 SERPINA3 ICOSLG H2AC18 CCR6
41 lung cancer 30.9 SERPINA3 MIR31 MIR21 MIR199A1 MIR196A1 MIR17
42 arteries, anomalies of 30.9 SERPINA3 MIR21 MIR199A1 MIR196A1 MIR17 MIR145
43 autonomic neuropathy 30.9 MLN GAST CCK
44 inherited metabolic disorder 30.9 SERPINA3 MIR21 MIR199A1 MIR196A1 MIR17 MIR142
45 constipation 30.9 MLN H2AC18 GAST CCK
46 endometriosis 30.9 MIR199A1 MIR145 MIR143 MIR142 MIR126
47 bile reflux 30.9 S100A8 GAST CCK
48 duodenum disease 30.8 S100A8 MIR196A1 GAST
49 gastroesophageal reflux 30.8 S100A8 MLN GAST CCK
50 bladder disease 30.8 MIR31 MIR21 MIR199A1 MIR196A1 MIR17 MIR145

Graphical network of the top 20 diseases related to Gastrointestinal System Disease:



Diseases related to Gastrointestinal System Disease

Symptoms & Phenotypes for Gastrointestinal System Disease

UMLS symptoms related to Gastrointestinal System Disease:


vomiting, nausea and vomiting, abdominal pain, constipation, diarrhea, nausea, halitosis, abdominal cramps, abdominal bloating, icterus, signs and symptoms, digestive, rectal tenesmus, decrease in appetite, dyspepsia, heartburn, gastrointestinal gas, anal discomfort, oral manifestations, digestive system symptom, vomiting alone, catarrh, flatulence, eructation, and gas pain, symptoms involving digestive system, other symptoms involving digestive system, odynophagia, swallowing problems, pathological conditions, signs and symptoms, signs and symptoms of ill-defined conditions, glossalgia, gastric irritation, abdomen, acute, eructation, flatulence, rectal pain, liver tender, abdominal discomfort, upper abdominal pain, lower abdominal pain, retching, dry throat, hyperemesis, abdominal distress, epigastric pain not food-related, right upper quadrant pain, epigastric food-related pain, upset stomach, abdominal fullness, salivary gland pain, abdominal distention, gaseous, anal pain, infantile colic, vomiting in newborn, change in bowel habits, stomach cramps (finding), gastrointestinal symptoms, sore lip, gastrointestinal pain, abdominal distress/pain as reason for lower g.i. examination, abdominal distress/pain as reason for upper g.i. examination, epigastric discomfort, blood in stool, peeling tongue

Drugs & Therapeutics for Gastrointestinal System Disease

Drugs for Gastrointestinal System Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 561)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
2
Acetaminophen Approved Phase 4 103-90-2 1983
3
Simethicone Approved Phase 4 8050-81-5
4
Amitriptyline Approved Phase 4 50-48-6 2160
5
Perphenazine Approved Phase 4 58-39-9 4748
6
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
7
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
8
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
9
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
10
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
11
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
12
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
13
Alfentanil Approved, Illicit Phase 4 71195-58-9 51263
14
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
15
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
16
Ibuprofen Approved Phase 4 15687-27-1 3672
17
Bisacodyl Approved Phase 4 603-50-9
18
Prucalopride Approved Phase 4 179474-81-8
19
Calcium carbonate Approved, Investigational Phase 4 471-34-1
20
Alverine Approved, Investigational Phase 4 150-59-4 3678
21
Mebeverine Approved, Investigational Phase 4 3625-06-7 62887
22
Bismuth subsalicylate Approved, Vet_approved Phase 4 14882-18-9 53629521
23
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
24
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
25
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
26
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
27
Sodium citrate Approved, Investigational Phase 4 68-04-2
28
leucovorin Approved Phase 4 58-05-9 6006 143
29
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
30
Metronidazole Approved Phase 4 443-48-1 4173
31
Clarithromycin Approved Phase 4 81103-11-9 84029
32
Potassium citrate Approved, Investigational, Vet_approved Phase 4 866-84-2
33
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
34
Silicon Approved, Investigational Phase 4 7440-21-3 4082203
35
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
36
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 11953898
37
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
38
Racepinephrine Approved Phase 4 329-65-7 838
39
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
40
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
41
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
42
Mannitol Approved, Investigational Phase 4 69-65-8 6251 453
43
Azithromycin Approved Phase 4 83905-01-5 447043 55185
44
Ustekinumab Approved, Investigational Phase 4 815610-63-0
45 Vedolizumab Approved Phase 4 943609-66-3
46
Pancrelipase Approved, Investigational Phase 4 53608-75-6
47
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
48
Mycophenolic acid Approved Phase 4 24280-93-1 446541
49
Ginseng Approved, Investigational, Nutraceutical Phase 4 50647-08-0
50
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 5283731 6433735

Interventional clinical trials:

(show top 50) (show all 923)
# Name Status NCT ID Phase Drugs
1 The Treatment of Periodontal Diseases. A Randomized, Blinded, Five Years Follow-up, Four-arm, Placebo Controlled Clinical Intervention Trial Unknown status NCT01318928 Phase 4 Metronidazol
2 The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Continuing or Discontinuing on Aspirin: a Multicenter, Double-blind, Placebo-controlled, Randomized Clinical Trial Unknown status NCT01549418 Phase 4 Aspirin (ASA);Placebo
3 Oral Resveratrol Before ERCP Redused Overall Pancreatitis in Patients Undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP): A Multi-center, Single-blinded, Randomized Controlled Trial Unknown status NCT02947932 Phase 4 Resveratrol;Indomethacin
4 Phase 4 Study of Helicobacter Pylori Eradication Therapy Unknown status NCT00990405 Phase 4 Lansoprzole+Amoxicillin+Clarithromycin
5 EVALUATION OF THE USE OF N-ACETYLCYSTEINE ATTENUATING CISPLATIN-INDUCED TOXICITIES BY OXIDATIVE STRESS IN HEAD AND NECK CANCER PATIENTS Unknown status NCT02241876 Phase 4 N-acetylcysteine
6 Randomized Controlled Trial Testing the Effect of Milk Formula Supplemented With L. Reuteri on Crying Time in Colicky Infants Less Than 3 Months Old Unknown status NCT02430831 Phase 4
7 Spectrum of Gastrointestinal Microbiota in Patients With IBS-D Before and After Treatment With VSL#3. Unknown status NCT01638208 Phase 4 VSL#3
8 Glucomannn for the Treatment of Abdominal Pain-related Functional Gastrointestinal Disorders in Childhood Randomized Double Blind Placebo Controlled Trial Completed NCT01495806 Phase 4 Glucomannan;placebo
9 Evaluation of the Effects of Enterogermina, 2 Billion Bacillus Clausii Spores, on the Intestinal Flora of Children Antibiotic Treated for Bacterial Upper Respiratory Tract Infections: Open, Pilot Study. Completed NCT00424905 Phase 4 Bacillus clausii
10 Comparison of the Eradication Rate Between 1- and 2-Week PPI Containing Therapies for Helicobacter Pylori Eradication Completed NCT02487511 Phase 4
11 Evaluation of the Efficacy of Amitriptyline in Children With Abdominal Pain of Non-Organic Origin Completed NCT00564525 Phase 4 Amitriptyline;Placebo
12 A Multicentre, Randomised, Double-Blind, Placebo Controlled, Crossover Trial On The Efficacy Of A Mixture Of Three Bifidobacteria In Children With Abdominal Pain-Associated Functional Gastrointestinal Disorders Completed NCT02566876 Phase 4 Mixture of three Bifidobacteria
13 Comparative Randomized, Single Dose, Two-way Crossover Open-label Study to Determine the Bioequivalence of Rabeprazole From Raperazole 20mg DR Tabs (GSK, Egypt) and PARIET 20 mg DR Tabs (JANSSEN, EGYPT) After a Single Oral Dose Administration of Each to Healthy Adults Under Fed Conditions Completed NCT02605395 Phase 4 IDIAZOLE 20mg DR tabs;PARIET 20 mg DR tabs
14 A Randomised, Multicentre, Single-Blind, Phase IV Study, of the Efficacy, Safety, and Acceptability of Moviprep® Versus Colopeg® in Colonoscopy Preparation. Completed NCT00605228 Phase 4 MOVIPREP;COLOPEG
15 Clinical Use of an Absorbable Coated Suture Material in Surgery (Safil) One Layer Running(A) vs. Two-Layer Suture Technique (B) Completed NCT00645684 Phase 4
16 Comparative Randomized, Single Dose, Two-way Crossover Open-label Study to Determine the Bioequivalence of Rabeprazole From Idiazole 20mg DR Tabs (GSK, Egypt)and PARIET 20 mg DR Tabs (JANSSEN, EGYPT) After a Single Oral Dose Administration of Each to Healthy Adults Under Fasting Conditions Completed NCT02446483 Phase 4 Idiazole 20mg DR tabs;PARIET 20 mg DR tabs
17 The Effects of Fentanyl and Alfentanil as an Adjunct to Propofol on Cognitive Functions for Sedation in Colonoscopy Completed NCT02267681 Phase 4 Fentanyl;Alfentanil;Propofol
18 The Effect of Vitamin D3 to Maintain Surgical Remission in Postoperative Crohn's Disease: a Placebo-controlled Randomized Trial Completed NCT02010762 Phase 4 Vitamin D;Placebo
19 Randomized Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy Completed NCT00526331 Phase 4
20 Assistance Robotics for the Surgical Treatment of the Abdominal Wall Hernia Completed NCT00908193 Phase 4
21 The Efficacy of Mutaflor(E. Coli Nissle 1917, Mutaflor®) for Chronic Constipation:Multicenter Study Completed NCT02726295 Phase 4 E. coli Nissle 1917(Mutaflor®);Placebo
22 The Effect of Esomeprazole (Nexium) on the Incidence and Severity of Gastrointestinal Adverse Events Associated With a Colonoscopy Purgative Completed NCT00225238 Phase 4 esomeprazole (PPI)
23 Efficacy and Tolerability of α-galactosidase in Treating Gas-related Symptoms in Children. A Randomized, Double-blind, Placebo-controlled Trial Completed NCT01595932 Phase 4
24 An Open-Label Trial of Duloxetine for the Treatment of Irritable Bowel Syndrome Without Comorbid Major Depressive Disorder Completed NCT00401258 Phase 4 duloxetine
25 An Open Observational Study For The Rabeprazole Administration In Adult Subjects With Helicobacter Pylori (H. Pylori) Infection Completed NCT00216450 Phase 4 rabeprazole sodium
26 The Effect of Korean Red Ginseng Supplementation on Glucose Control in Subjects With Impaired Fasting Glucose, Impaired Glucose Tolerance or Newly-diagnosed Type 2 Diabetes Mellitus Completed NCT01911663 Phase 4
27 Comparison of the I-gel Laryngeal Mask and the Classic Laryngeal Mask in Patients With a BMI>25 During Elective Surgery Completed NCT01003327 Phase 4
28 Open, Single Centre, Pilot Study to Investigate a Steroid Free Immunosuppressive Regimen for De Novo Renal Transplant Recipients Followed by Randomisation to Calcineurin Inhibitor Containing or Calcineurin Inhibitor Free Immunosuppression Completed NCT00306397 Phase 4 Rapamycin
29 An Open-label, Randomised, Crossover, Reader Blinded, Study to Compare the Effect of Polyethylene Glycol 3350, Bisacodyl and Prucalopride on Colonic Motility Assessed With Intraluminal Colonic Manometry in Healthy Subjects Completed NCT03279341 Phase 4 polyethylene glycol;Bisacodyl;Prucalopride
30 Metronidazole for the Treatment of Dientamoebiasis in Children in Denmark - A Randomized, Placebo-controlled, Double-blinded Clinical Trial Completed NCT01314976 Phase 4 Metronidazole;Placebo
31 Effect of Proton Pump Inhibitor on Gastric Emptying and Satiety Function in Patients With Functional Dyspepsia Completed NCT00951431 Phase 4 Esomeprazole;Placebo
32 Efficacy of the Combination Therapy With Alverine-simeticone and i3.1 Probiotic Formula in the Quality of Life of Patients With IBS-D or IBS-M in Hospital Juarez Mexico Completed NCT04145856 Phase 4
33 Efficacy of Calcifediol Supplementation in Asthma Control in Asthmatic Patients With Vitamin D Deficiency (ACViD) Completed NCT02805907 Phase 4 Calcifediol;Placebo
34 Short Protocol Barostat for Assessment of Anorectal Function Versus Standard Protocol Barostat in Healthy Volunteers Completed NCT01456442 Phase 4
35 Reduction of Postoperative Gastrointestinal Dysmotility Following Total Laparoscopic Hysterectomy: a Randomized Control Trial. Completed NCT03800745 Phase 4 Colace 100Mg Capsule;Miralax
36 Absorption of Orally Ingested Phosphate in Head and Neck Cancer Patients With and Without Refeeding Syndrome Completed NCT02880072 Phase 4
37 Comparing With Traditional Nitrogen Calorie Parenteral Nutrition Support, the Impact of Low Calorie and Low Nitrogen Intake on the Clinical Outcome of Gastrointestinal Postoperative Patients, Multicentre Post-Marketing Clinical Study Completed NCT00247338 Phase 4 low calorie, low nitrogen parenteral nutrition for patient with NRS score 3
38 CALCIUM CITRATE vs CALCIUM CARBONATE FOR THE MANAGEMENT OF CHRONIC HYPOPARATHYROIDISM Completed NCT03425747 Phase 4 Calcium Carbonate;Calcium Citrate
39 Single-Site, Double-Blind, Flexible-Dose, Placebo-Controlled Study of the Efficacy, Tolerability, & Safety of Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS) Completed NCT00610909 Phase 4 Paroxetine CR;Placebo
40 Role of Gastroesophageal Acid Reflux at Squamo-columnar Junction in Functional Dyspepsia Completed NCT01349413 Phase 4 Esomeprazole 20mg
41 The Effects of Acetaminophen and Ibuprofen With and Without Magnesium in the Treatment of Primary Migraine in Childhood Completed NCT01756209 Phase 4 Magnesium 400Mg;Ibuprofen 10 mg/kg;acetaminophen 15 mg/kg
42 A Greek, Single Center, Randomized, Double Blind Controlled Clinical Study Comparing the 10-day Versus the 14-day Concomitant Proton Pump Inhibitor [PPI] + Amoxicillin + Metronidazole + Clarithromycin (PAMC) Therapeutic Scheme as First-line Treatment Strategy for the Eradication of H. Pylori Infection Completed NCT02959255 Phase 4 Esomeprazole
43 Propolis Improves Periodontal Status and Glycemic Control in Subjects With Type 2 Diabetes Mellitus and Chronic Periodontitis: a Randomized Clinical Trial Completed NCT02794506 Phase 4 Propolis;Placebo
44 Metabolic and Vascular Effects of Silybin in Hypertensive Patients With High One-hour Post-load Plasma Glucose: a Single Arm Pilot Study Completed NCT03538327 Phase 4 Silybin
45 Opioid Free Versus Opioid Balanced Anesthesia in Middle Ear Surgery. Completed NCT03809949 Phase 4 Fentanyl Opioid anesthesia;Saline Nonopioid anesthesia
46 Influence of Dexmedetomidine and Lidocaine on Opioid Consumption, Cognitive Function and Incidence of Neuropathic Pain in Laparoscopic Intestine Resection Completed NCT02616523 Phase 4 Dexmedetomidine;Lidocaine;Fentanyl
47 The Effect of Corticotrophin-releasing Hormone (CRH) on Esophageal Motility in Healthy Volunteers Completed NCT02736734 Phase 4 CRH
48 The Safety and Immunogenicity of 10μg/0.5ml Recombinant Hepatitis B Vaccines(Saccharomyces Cerevisiae) in the Healthy Neonates Recruiting NCT02764671 Phase 4
49 Cystic Fibrosis and Gut Dysmotility: The Effect of Polyethylene Glycol (PEG) on Intestinal Transit Recruiting NCT04210427 Phase 4 Polyethylene Glycol 3350
50 10 Day Concomitant Versus 14 Day Hybrid Regimen as First Line H. Pylori Eradication Treatment in a High Clarithromycin Resistance Area. A Multicenter Randomized Equivalence Trial Recruiting NCT03592069 Phase 4 10 day concomitant regimen;14 day hybrid regimen

Search NIH Clinical Center for Gastrointestinal System Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Belladonna Alkaloids
belladonna extract, USP
BELLADONNA LEAF
Dicyclomine
Dicyclomine Hydrochloride
prednisolone
prednisolone acetate
PREDNISOLONE ACETATE PWDR
PREDNISOLONE PWDR
Prednisolone sodium phosphate
prednisolone tebutate
Prednisone
PREDNISONE PWDR
Sacrosidase

Cochrane evidence based reviews: digestive system diseases

Genetic Tests for Gastrointestinal System Disease

Anatomical Context for Gastrointestinal System Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Gastrointestinal System Disease:

19
Gastrointestinal Tract

MalaCards organs/tissues related to Gastrointestinal System Disease:

40
Testes, Liver, Colon, Small Intestine, Brain, Pancreas, Bone

Publications for Gastrointestinal System Disease

Articles related to Gastrointestinal System Disease:

(show top 50) (show all 4682)
# Title Authors PMID Year
1
The vanilloid receptor TRPV1: role in cardiovascular and gastrointestinal protection. 54 61
19879868 2010
2
Ghrelin in gastrointestinal diseases and disorders: a possible role in the pathophysiology and clinical implications (review). 61 54
19885611 2009
3
Lactoferrin in gastrointestinal disease. 61 54
19652425 2009
4
Application of ghrelin to gastrointestinal diseases. 61 54
18821473 2008
5
Cholecystokinin. 61 54
17940422 2007
6
Prevalence of Helicobacter pylori cagA, iceA and babA2 alleles in Brazilian patients with upper gastrointestinal diseases. 54 61
17181989 2006
7
Association of H pylori cagA and vacA genotypes and IL-8 gene polymorphisms with clinical outcome of infection in Iranian patients with gastrointestinal diseases. 61 54
16937534 2006
8
Tissue distribution and plasma clearance of heparin-binding EGF-like growth factor (HB-EGF) in adult and newborn rats. 54 61
16364500 2006
9
Circulating ghrelin levels in patients with various upper gastrointestinal diseases. 54 61
15906753 2005
10
Immunohistochemical distribution of vanilloid receptor, calcitonin-gene related peptide and substance P in gastrointestinal mucosa of patients with different gastrointestinal disorders. 54 61
16259736 2005
11
Topographical localisation of cagA positive and cagA negative Helicobacter pylori strains in the gastric mucosa; an in situ hybridisation study. 54 61
15280402 2004
12
T helper-2 immunity regulates bronchial hyperresponsiveness in eosinophil-associated gastrointestinal disease in mice. 61 54
15236177 2004
13
cagA and vacA genotype of Helicobacter pylori associated with gastric diseases in Xi'an area. 61 54
12918116 2003
14
Involvement of cholecystokinin/gastrin-related peptides and their receptors in clinical gastrointestinal disorders. 61 54
12688377 2002
15
Combination of HCGbeta, CA 19-9 and CEA with logistic regression improves accuracy in gastrointestinal malignancies. 61 54
12168865 2002
16
[Helicobacter pylori genotypes in non atrophic gastritis are different of the found in peptic ulcer, premalignant lesions and gastric cancer in Colombia]. 61 54
11974526 2002
17
ALX-0600 (NPS Allelix Corp). 54 61
11566007 2001
18
Association of Helicobacter pylori genotype with gastroesophageal reflux disease and other upper gastrointestinal diseases. 54 61
10710054 2000
19
Direct determination of Helicobacter pylori vacA genotypes and cagA gene in gastric biopsies and relationship to gastrointestinal diseases. 61 54
10364019 1999
20
High frequency of cytotoxin-associated gene A in Helicobacter pylori isolated from asymptomatic subjects and peptic ulcer patients in Taiwan. 54 61
9706771 1998
21
[Measurement of fecal lactoferrin for diagnosis on pediatric gastrointestinal disease]. 61 54
9437905 1997
22
A multicentre evaluation of tumour marker determinations using the automatic Enzymun-Test Systems ES 300 and ES 600/700. 61 54
8704058 1996
23
Chromosomal localization of the gastric and brain receptors for cholecystokinin (CCKAR and CCKBR) in human and mouse. 61 54
7759110 1995
24
Bile acids in human plasma interfere with cholecystokinin bioassay using dispersed pancreatic acini. 61 54
1995267 1991
25
Fecal isoamylase activity in patients with pancreatic diseases. 54 61
1704633 1991
26
Mechanism of Huang-lian-Jie-du decoction and its effective fraction in alleviating acute ulcerative colitis in mice: Regulating arachidonic acid metabolism and glycerophospholipid metabolism. 61
32417423 2020
27
Traditional Chinese Medicine Li-Zhong-Tang accelerates the healing of indomethacin-induced gastric ulcers in rats by affecting TLR-2/MyD88 signaling pathway. 61
32442585 2020
28
Bacillus cereus spores and toxins - The potential role of biofilms. 61
32336372 2020
29
Ghrelin acts in the brain to block colonic hyperpermeability in response to lipopolysaccharide through the vagus nerve. 61
32442542 2020
30
Hepatoprotection and hepatotoxicity of Chinese herb Rhubarb (Dahuang): How to properly control the "General (Jiang Jun)" in Chinese medical herb. 61
32559851 2020
31
Usefulness of a Point-of-Care Analyzer to Measure Cardiac Troponin I and D-Dimer Concentrations in Critically Ill Horses With Gastrointestinal Diseases. 61
32534789 2020
32
Machine learning algorithm as a diagnostic tool for hypoadrenocorticism in dogs. 61
32006871 2020
33
Association between major depressive disorder and multiple disease outcomes: a phenome-wide Mendelian randomisation study in the UK Biobank. 61
31427754 2020
34
Association Between Endoscopic and Histologic Findings in a Multicenter Retrospective Cohort of Patients with Non-esophageal Eosinophilic Gastrointestinal Disorders. 61
31773359 2020
35
Duodenal bacterial load as determined by quantitative polymerase chain reaction in asymptomatic controls, functional gastrointestinal disorders and inflammatory bowel disease. 61
32412673 2020
36
Sutterella Species, IgA-degrading Bacteria in Ulcerative Colitis. 61
32544438 2020
37
Donning a New Approach to the Practice of Gastroenterology: Perspectives From the COVID-19 Pandemic Epicenter. 61
32330565 2020
38
Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. 61
32405603 2020
39
Costunolide improved dextran sulfate sodium-induced acute ulcerative colitis in mice through NF-κB, STAT1/3, and Akt signaling pathways. 61
32413737 2020
40
May rotavirus vaccine be affect food allergy prevalence? 61
32530362 2020
41
Approaches for designing and discovering purinergic drugs for gastrointestinal diseases. 61
32228110 2020
42
Consideration for Use of Probiotics in Gastrointestinal Diseases: Clinical Decision Support Tool. 61
32544395 2020
43
Elemental Analysis of Medicinal Plants Used for the Treatment of Some Gastrointestinal Diseases in Ethiopia Using INAA Technique. 61
32557101 2020
44
Late complications associated with totally implantable venous access port implantation via the internal jugular vein. 61
31724073 2020
45
Adenovirus in the omics era - a multipronged strategy. 61
31811727 2020
46
Adherent-invasive Escherichia coli (AIEC): Cause or consequence of inflammation, dysbiosis, and rupture of cellular joints in patients with IBD? 61
31898324 2020
47
Graphdiyne nanoradioprotector with efficient free radical scavenging ability for mitigating radiation-induced gastrointestinal tract damage. 61
32200103 2020
48
Study on the Application of Ultrasonic Image Analysis Technology Combined with the Analysis of Intestinal Nervous System in the Treatment of Intestinal Duplication in Children. 61
31931245 2020
49
Prevalence and Molecular Differentiation of Entamoeba histolytica, Entamoeba dispar, Entamoeba moshkovskii, and Entamoeba hartmanni in Egypt. 61
32557084 2020
50
Heterologous Expression of the Leuconostoc Bacteriocin Leucocin C in Probiotic Yeast Saccharomyces boulardii. 61
32567021 2020

Variations for Gastrointestinal System Disease

Expression for Gastrointestinal System Disease

Search GEO for disease gene expression data for Gastrointestinal System Disease.

Pathways for Gastrointestinal System Disease

Pathways related to Gastrointestinal System Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.77 MIR31 MIR21 MIR199A1 MIR17 MIR145 MIR143
2 10.27 MIR199A1 MIR145
3 9.8 GAST CCK

GO Terms for Gastrointestinal System Disease

Cellular components related to Gastrointestinal System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.4 SERPINA3 S100A8 MIR31 MIR21 MIR199A1 MIR17
2 extracellular vesicle GO:1903561 9.26 MIR21 MIR17 MIR126 MIR122

Biological processes related to Gastrointestinal System Disease according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein kinase B signaling GO:0051897 9.8 MIR21 MIR199A1 MIR143 MIR126
2 positive regulation of inflammatory response GO:0050729 9.74 S100A8 MIR21 MIR126
3 negative regulation of inflammatory response GO:0050728 9.71 MIR31 MIR145 MIR142 MIR126
4 positive regulation of blood vessel endothelial cell migration GO:0043536 9.65 MIR31 MIR143 MIR126
5 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.58 MIR199A1 MIR17
6 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.56 MIR199A1 MIR17
7 leukocyte migration involved in inflammatory response GO:0002523 9.55 S100A8 CCR6
8 positive regulation of metalloendopeptidase activity GO:1904685 9.54 MIR21 MIR17
9 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.54 MIR21 MIR199A1 MIR145
10 angiotensin-activated signaling pathway GO:0038166 9.52 MIR145 MIR143
11 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.51 MIR21 MIR17
12 aorta smooth muscle tissue morphogenesis GO:0060414 9.46 MIR145 MIR143
13 miRNA mediated inhibition of translation GO:0035278 9.46 MIR31 MIR21 MIR17 MIR145
14 regulation of phenotypic switching GO:1900239 9.43 MIR145 MIR143
15 gene silencing by miRNA GO:0035195 9.36 MIR518A1 MIR31 MIR21 MIR199A1 MIR196A1 MIR17
16 positive regulation of angiogenesis GO:0045766 9.35 MIR31 MIR21 MIR199A1 MIR143 MIR126
17 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.32 MIR17 MIR143
18 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.26 MIR145 MIR143

Molecular functions related to Gastrointestinal System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.32 MIR518A1 MIR31 MIR21 MIR199A1 MIR196A1 MIR17

Sources for Gastrointestinal System Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....